ENCORE: Topline Results of a Phase Three Open-label Extension and Randomized-withdrawal Trial of AXS-12 in Narcolepsy (P6-14.006)

Key Points

• This research aims to assess the long-term efficacy and safety of AXS-12 in narcolepsy type 1 patients post-SYMPHONY study.
• Conducted as a Phase Three open-label extension and randomized-withdrawal trial.
• Involved participants who completed the Phase 3 SYMPHONY study.
• Demonstrated significant improvement in narcolepsy symptoms with AXS-12.
• Reported an overall favorable safety profile for long-term use of AXS-12.